Century Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP EPS of -$0.17 vs. -$0.11 expected. Collaboration revenue was $0 in-line with expectations following the BMS contract termination in 2025. The earnings miss was primarily driven by a $11.1M non-cash loss on lease termination as part of footprint optimization, although R&D and G&A expenses decreased YoY due to prior staff reductions. Cash runway is extended into Q1 2029 following a $126.4M private placement in January 2026.